naltrexone + bupropion (MYSIMBA°)

October 2015
Prescrire International;Oct2015, Vol. 24 Issue 164, p229
No abstract available.


Related Articles

  • Naltrexone ER/bupropion ER in obesity management: a guide to its use. Greig, Sarah; Keating, Gillian // Drugs & Therapy Perspectives;Dec2015, Vol. 31 Issue 12, p417 

    Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave, Mysimbaâ„¢) is an effective adjunct to reduced-calorie diet and increased physical activity for chronic bodyweight management in adults who are either obese, or overweight with at least one...

  • Naltrexone ER/Bupropion ER: A Review in Obesity Management. Greig, Sarah; Keating, Gillian // Drugs;Jul2015, Vol. 75 Issue 11, p1269 

    Oral naltrexone extended-release/bupropion extended-release (naltrexone ER/bupropion ER; Contrave, Mysimba™) is available as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥30 kg/m (i.e. obese) or a BMI of...

  • Naltrexone/Bupropion (Contrave) for Weight Loss. EARLY, JESSICA; WHITTEN, JEAN SUZIN // American Family Physician;4/15/2015, Vol. 91 Issue 8, p555 

    The article reviews the drug naltrexone/bupropion (Contrave) for weight loss.

  • Drugs in Clinical Development for Obesity.  // Pharmaceutical Medicine - New Zealand;2012, Vol. 26 Issue 6, p405 

    A chart is presented that lists drugs that are in clinical development for the treatment of obesity which include Cetilistat, Liraglutide and Naltrexone/bupropion.

  • Naltrexone plus bupropion for weight loss. Elliot, William T. // Infectious Disease Alert;Oct2010 Clinical Bri, p2 

    The article focuses on a study on the importance of Naltrexone plus bupropion on patients who have tried to lose weight, which was published in a 2010 issue of "Lancet."

  • Naltrexone plus bupropion for weight loss.  // OB/GYN Clinical Alert;Oct 2010 Pharmacolog, p2 

    The article presents a study on the therapeutic efficiency of naltrexone plus bupropion to the lifestyle changes of patients who attempted to lose weight in the U.S.

  • Naltrexone plus bupropion for weight loss. Elliott, William T. // Critical Care Alert;Oct2010 Pharmacology, p2 

    The article reports on the results of a study which revealed the significance of naltrexone plus bupropion in weight loss among 1,742 people in the U.S.

  • Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Rukstalis, Margaret; Jepson, Christopher; Strasser, Andrew; Lynch, Kevin G.; Perkins, Kenneth; Patterson, Freda; Lerman, Caryn // Psychopharmacology;Jun2005, Vol. 180 Issue 1, p41 

    Presents a study which examined the effects of an acute dose of naltrexone on the relative reinforcing value of nicotine from cigarette smoking. Examples of effective medications for smoking cessation; Similarity between bupropion and amphetamine; Conclusion of the study.

  • Dual Regimen Benefits Obese Patients. STEIN, JILL // Renal & Urology News;Aug2011, Vol. 10 Issue 8, p20 

    The article offers information on the dual regimen benefits using the combination of sustained-release naltrexone and bupropion which resulted in improved cardiovascular risk markers and sustained weight loss in obese patients.

  • FDA advisory committee recommends approval of combination weight-loss drug. Smith, Steven R. // Endocrine Today;Jan2011, Vol. 9 Issue 1, p8 

    This article reports on the decision of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to recommend the approval of the novel combination of bupropion plus naltrexone for the treatment of obesity.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics